Detalhe da pesquisa
1.
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab.
Cell
; 171(4): 934-949.e16, 2017 Nov 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29033130
2.
Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Cancer Immunol Immunother
; 73(7): 116, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38713408
3.
Increased risk of recurrence and disease-specific death following delayed postoperative radiation for Merkel cell carcinoma.
J Am Acad Dermatol
; 90(2): 261-268, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37778663
4.
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinoma.
Cancer Immunol Immunother
; 72(11): 3839-3850, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37733060
5.
Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(4): 387-405, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35390769
6.
Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot study.
Support Care Cancer
; 30(5): 3829-3838, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35034197
7.
Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients.
J Am Acad Dermatol
; 84(2): 330-339, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32707254
8.
How we treat Merkel cell carcinoma: within and beyond current guidelines.
Future Oncol
; 17(11): 1363-1377, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33511866
9.
Predictive lifestyle markers for efficacy of cancer immune checkpoint inhibitors: a commentary.
Future Oncol
; 17(4): 363-369, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33397134
10.
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med
; 377(19): 1824-1835, 2017 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28891423
11.
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.
J Natl Compr Canc Netw
; 18(3): 230-241, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32135517
12.
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.
N Engl J Med
; 374(26): 2542-52, 2016 Jun 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-27093365
13.
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
Cancer Immunol Immunother
; 68(4): 609-618, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30721341
14.
Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors.
J Natl Compr Canc Netw
; 17(6): 750-757, 2019 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31200356
15.
Management of Immunotherapy-Related Toxicities, Version 1.2019.
J Natl Compr Canc Netw
; 17(3): 255-289, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30865922
16.
Prognosis of Merkel cell carcinoma patients with autoimmune disorders, other types of immune dysfunction, or immunocompetent status: Analysis of 762 patients.
J Am Acad Dermatol
; 90(5): 1018-1020, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38184277
17.
Correction to: Extended duration of treatment using reducedfrequency dosing of antiPD1 therapy in patients with advanced melanoma and Merkel cell carcinoma.
Cancer Immunol Immunother
; 72(12): 4471, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37979010
18.
Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
J Natl Compr Canc Netw
; 16(6): 782-790, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29891528
19.
Merkel cell carcinoma: Current US incidence and projected increases based on changing demographics.
J Am Acad Dermatol
; 78(3): 457-463.e2, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29102486
20.
Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study.
Cancer
; 123(8): 1464-1474, 2017 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27925665